These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10435727)

  • 1. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation.
    Poonkuzhali B; Srivastava A; Quernin MH; Dennison D; Aigrain EJ; Kanagasabapathy AS; Krishnamoorthy R; Chandy M
    Bone Marrow Transplant; 1999 Jul; 24(1):5-11. PubMed ID: 10435727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
    Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
    Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia.
    Pawlowska AB; Blazar BR; Angelucci E; Baronciani D; Shu XO; Bostrom B
    Bone Marrow Transplant; 1997 Dec; 20(11):915-20. PubMed ID: 9422469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
    Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
    Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
    Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages.
    Shaw PJ; Nath C; Berry A; Earl JW
    Bone Marrow Transplant; 2004 Aug; 34(3):197-205. PubMed ID: 15195074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children.
    Chattergoon DS; Saunders EF; Klein J; Calderwood S; Doyle J; Freedman MH; Koren G
    Bone Marrow Transplant; 1997 Sep; 20(5):347-54. PubMed ID: 9339748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of busulfan area under the curve with veno-occlusive disease following BMT.
    Dix SP; Wingard JR; Mullins RE; Jerkunica I; Davidson TG; Gilmore CE; York RC; Lin LS; Devine SM; Geller RB; Heffner LT; Hillyer CD; Holland HK; Winton EF; Saral R
    Bone Marrow Transplant; 1996 Feb; 17(2):225-30. PubMed ID: 8640171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
    Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation.
    Balasubramanian P; Chandy M; Krishnamoorthy R; Srivastava A
    Bone Marrow Transplant; 2001 Nov; 28(9):821-5. PubMed ID: 11781641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.
    Hassan M; Fasth A; Gerritsen B; Haraldsson A; Syrůcková Z; van den Berg H; Sandström M; Karlsson M; Kumlien S; Vossen J
    Bone Marrow Transplant; 1996 Nov; 18(5):843-50. PubMed ID: 8932835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
    Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
    Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
    Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Busulphan level and early mortality in thalassaemia patients after BMT.
    Li CK; Yuen PM; Wong R; Pang CP; Lai WK; Law E; Shing MM; Chik KW; Leung TF
    Bone Marrow Transplant; 1999 Feb; 23(4):307-10. PubMed ID: 10100572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparative regimens for marrow transplantation containing busulphan are associated with haemorrhagic cystitis and hepatic veno-occlusive disease but a short duration of leucopenia and little oro-pharyngeal mucositis.
    Atkinson K; Biggs J; Noble G; Ashby M; Concannon A; Dodds A
    Bone Marrow Transplant; 1987 Dec; 2(4):385-94. PubMed ID: 3332186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.
    Zwaveling J; Bredius RG; Cremers SC; Ball LM; Lankester AC; Teepe-Twiss IM; Egeler RM; den Hartigh J; Vossen JM
    Bone Marrow Transplant; 2005 Jan; 35(1):17-23. PubMed ID: 15502853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.
    Lee JH; Choi SJ; Lee JH; Kim SE; Park CJ; Chi HS; Lee MS; Lee JS; Kim WK; Lee KH
    Ann Hematol; 2005 May; 84(5):321-30. PubMed ID: 15580502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia--the role of busulfan pharmacokinetics in determining outcome.
    Chandy M; Balasubramanian P; Ramachandran SV; Mathews V; George B; Dennison D; Krishnamoorthy R; Srivastava A
    Bone Marrow Transplant; 2005 Nov; 36(10):839-45. PubMed ID: 16151422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
    Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
    Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.